Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | TERT | O14746 | 2/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | ESRRG | P62508 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | DRD4 | P21917 | 3/20 | 0.38 |
| ▸ | DRD3 | P35462 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30480094 | 1.00 | LMNA (0.48) | LMNAMAPK1HTTSMN1; SMN2HTR6 | |
| SCHEMBL4056753 | 0.79 | CA1 (0.51) | LMNAHTTSMN1; SMN2HTR6HTR1A | |
| SCHEMBL28132995 | 0.79 | LMNA (0.42) | LMNAMAPK1HTTSMN1; SMN2HTR6 | |
| SCHEMBL1937236 | 0.79 | XDH (0.43) | LMNAMAPK1HTTSMN1; SMN2HSD11B1 | |
| SCHEMBL598333 | 0.76 | CA1 (0.50) | LMNAMAPK1HTTSMN1; SMN2HTR1A | |
| SCHEMBL13933202 | 0.76 | CA1 (0.49) | LMNAHTTSMN1; SMN2HTR6HTR1A | |
| SCHEMBL14506101 | 0.73 | HSD11B1 (0.47) | HTR1AHTR1DHTR1BHSD11B1CA1 | |
| SCHEMBL1713420 | 0.73 | CA1 (0.61) | LMNAMAPK1HTTSMN1; SMN2HTR1A | |
| SCHEMBL29839512 | 0.73 | CA1 (0.61) | LMNAMAPK1HTTSMN1; SMN2HTR1A | |
| SCHEMBL14533419 | 0.72 | CA1 (0.42) | LMNAHTTSMN1; SMN2HTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2024-06-27 | — | — | US | disclosed |
| CN-110483335-B | Amyloid targeting agents and methods of use thereof | 阿米达斯公司 | 2023-08-11 | — | — | CN | disclosed |
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| EP-3119761-B1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | AMYDIS DIAGNOSTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3119761-B1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | AMYDIS DIAGNOSTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210371390-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2021-12-02 | — | — | US | disclosed |
| US-20170248616-A1 | IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT | Amydis, Inc. | 2017-08-31 | — | — | US | disclosed |
| US-20170248616-A1 | IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT | Amydis, Inc. | 2017-08-31 | — | — | US | disclosed |
| EP-3191107-A2 | IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT | Amydis Diagnostics, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-3119761-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis Diagnostics, Inc. (US) | 2017-01-25 | — | — | EP | disclosed |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2016-11-10 | — | — | US | disclosed |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2016-11-10 | — | — | US | disclosed |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2016-11-10 | — | — | US | disclosed |
| WO-2016040891-A2 | IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT | AMYDIS DIAGNOSTICS (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2015143185-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | AMYDIS DIAGNOSTICS (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015143185-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | AMYDIS DIAGNOSTICS (US) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | LMNA 1263/4885MAPK1 4384/4885HTT 54/4885 |
| US-20210371390-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | LMNA 1263/4885MAPK1 4384/4885HTT 54/4885 |
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | LMNA 1263/4885MAPK1 4384/4885HTT 54/4885 |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, APBA1, CRYAA | LMNA 1283/4885MAPK1 4449/4885HTT 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.